Search

Your search keyword '"Issa, Jean-Pierre J."' showing total 1,091 results
Start Over Author "Issa, Jean-Pierre J."
1,091 results on '"Issa, Jean-Pierre J."'

5. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Author

Fenaux, Pierre, Gobbi, Marco, Kropf, Patricia L., Issa, Jean-Pierre J., Roboz, Gail J., Mayer, Jiri, Krauter, Jürgen, Robak, Tadeusz, Kantarjian, Hagop, Novak, Jan, Jedrzejczak, Wieslaw. W., Thomas, Xavier, Ojeda-Uribe, Mario, Miyazaki, Yasushi, Min, Yoo Hong, Yeh, Su-Peng, Brandwein, Joseph, Gercheva-Kyuchukova, Liana, Demeter, Judit, Griffiths, Elizabeth, Yee, Karen, Döhner, Konstanze, Hao, Yong, Keer, Harold, Azab, Mohammad, and Döhner, Hartmut

Published
2023
Full Text
View/download PDF

7. DNA methylation aging clocks: challenges and recommendations

Author

Bell, Christopher G, Lowe, Robert, Adams, Peter D, Baccarelli, Andrea A, Beck, Stephan, Bell, Jordana T, Christensen, Brock C, Gladyshev, Vadim N, Heijmans, Bastiaan T, Horvath, Steve, Ideker, Trey, Issa, Jean-Pierre J, Kelsey, Karl T, Marioni, Riccardo E, Reik, Wolf, Relton, Caroline L, Schalkwyk, Leonard C, Teschendorff, Andrew E, Wagner, Wolfgang, Zhang, Kang, and Rakyan, Vardhman K

Subjects
Human Genome, Genetics, Aging, Generic health relevance, Animals, Biological Clocks, DNA Methylation, Epigenesis, Genetic, Genome, Human, Genome-Wide Association Study, Humans, Environmental Sciences, Biological Sciences, Information and Computing Sciences, Bioinformatics
Abstract

Epigenetic clocks comprise a set of CpG sites whose DNA methylation levels measure subject age. These clocks are acknowledged as a highly accurate molecular correlate of chronological age in humans and other vertebrates. Also, extensive research is aimed at their potential to quantify biological aging rates and test longevity or rejuvenating interventions. Here, we discuss key challenges to understand clock mechanisms and biomarker utility. This requires dissecting the drivers and regulators of age-related changes in single-cell, tissue- and disease-specific models, as well as exploring other epigenomic marks, longitudinal and diverse population studies, and non-human models. We also highlight important ethical issues in forensic age determination and predicting the trajectory of biological aging in an individual.

Published
2019

11. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

Author

Tsimberidou, Apostolia M, Said, Rabih, Culotta, Kirk, Wistuba, Ignacio, Jelinek, Jaroslav, Fu, Siqing, Falchook, Gerald, Naing, Aung, Piha-Paul, Sarina, Zinner, Ralph, Siddik, Zahid H, He, Guangan, Hess, Kenneth, Stewart, David J, Kurzrock, Razelle, and Issa, Jean-Pierre J

Subjects
Biological Sciences, Genetics, Clinical Research, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, DNA methylation, Platinum resistance, Copper/platinum transporter, Clinical Sciences, Paediatrics and Reproductive Medicine
Abstract

BackgroundDemethylation process is necessary for the expression of various factors involved in chemotherapy cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1. We hypothesized that azacitidine and oxaliplatin combination therapy may restore platinum sensitivity. We treated patients with cancer relapsed/refractory to any platinum compounds (3 + 3 study design) with azacitidine (20 to 50 mg/m(2)/day intravenously (IV) over 15 to 30 min, D1 to 5) and oxaliplatin (15 to 30 mg/m(2)/day, IV over 2 h, D2 to 5) (maximum, six cycles). Platinum content, LINE1 methylation (surrogate of global DNA methylation), and CTR1 expression changes (pre- vs. post-treatment) were assessed. Drug pharmacokinetics were analyzed.ResultsThirty-seven patients were treated. No dose-limiting toxicity (DLT) was noted at the maximum dose. The most common adverse events were anemia and fatigue. Two (5.4%) patients had stable disease and completed six cycles of therapy. Oxaliplatin (D2) and azacitidine (D1 and 5) mean systemic exposure based on plasma AUCall showed dose-dependent interaction whereby increasing the dose of oxaliplatin reduced the mean azacitidine exposure and vice versa; however, no significant differences in other non-compartmental modeled parameters were observed. Blood samples showed universal reduction in global DNA methylation. In tumor samples, hypomethylation was only observed in four out of seven patients. No correlation between blood and tumor demethylation was seen. The mean cytoplasmic CTR1 score decreased. The pre-dose tumor oxaliplatin levels ranged from

Published
2015

12. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas

Author

Hu, Xin, Estecio, Marcos R., Chen, Runzhe, Reuben, Alexandre, Wang, Linghua, Fujimoto, Junya, Carrot-Zhang, Jian, McGranahan, Nicholas, Ying, Lisha, Fukuoka, Junya, Chow, Chi-Wan, Pham, Hoa H. N., Godoy, Myrna C. B., Carter, Brett W., Behrens, Carmen, Zhang, Jianhua, Antonoff, Mara B., Sepesi, Boris, Lu, Yue, Pass, Harvey I., Kadara, Humam, Scheet, Paul, Vaporciyan, Ara A., Heymach, John V., Wistuba, Ignacio I., Lee, J. Jack, Futreal, P. Andrew, Su, Dan, Issa, Jean-Pierre J., and Zhang, Jianjun

Published
2021
Full Text
View/download PDF

14. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Author

Garcia-Manero, Guillermo, Roboz, Gail, Walsh, Katherine, Kantarjian, Hagop, Ritchie, Ellen, Kropf, Patricia, O'Connell, Casey, Tibes, Raoul, Lunin, Scott, Rosenblat, Todd, Yee, Karen, Stock, Wendy, Griffiths, Elizabeth, Mace, Joseph, Podoltsev, Nikolai, Berdeja, Jesus, Jabbour, Elias, Issa, Jean-Pierre J, Hao, Yong, Keer, Harold N, Azab, Mohammad, and Savona, Michael R

Published
2019
Full Text
View/download PDF

16. Postmortem toxicology findings from the Camden Opioid Research Initiative

Author

Kusic, Dara M., primary, Heil, Jessica, additional, Zajic, Stefan, additional, Brangan, Andrew, additional, Dairo, Oluseun, additional, Heil, Stacey, additional, Feigin, Gerald, additional, Kacinko, Sherri, additional, Buono, Russell J., additional, Ferraro, Thomas N., additional, Rafeq, Rachel, additional, Haroz, Rachel, additional, Baston, Kaitlan, additional, Bodofsky, Elliot, additional, Sabia, Michael, additional, Salzman, Matthew, additional, Resch, Alissa, additional, Madzo, Jozef, additional, Scheinfeldt, Laura B., additional, Issa, Jean-Pierre J., additional, and Jelinek, Jaroslav, additional

Published
2023
Full Text
View/download PDF

17. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer

Author

Zhang, Hanghang, Pandey, Somnath, Travers, Meghan, Sun, Hongxing, Morton, George, Madzo, Jozef, Chung, Woonbok, Khowsathit, Jittasak, Perez-Leal, Oscar, Barrero, Carlos A., Merali, Carmen, Okamoto, Yasuyuki, Sato, Takahiro, Pan, Joshua, Garriga, Judit, Bhanu, Natarajan V., Simithy, Johayra, Patel, Bela, Huang, Jian, Raynal, Noël J.-M., Garcia, Benjamin A., Jacobson, Marlene A., Kadoch, Cigall, Merali, Salim, Zhang, Yi, Childers, Wayne, Abou-Gharbia, Magid, Karanicolas, John, Baylin, Stephen B., Zahnow, Cynthia A., Jelinek, Jaroslav, Graña, Xavier, and Issa, Jean-Pierre J.

Published
2018
Full Text
View/download PDF

19. Epigenetic Inactivation of CHFR in Human Tumors

Author

Toyota, Minoru, Sasaki, Yasushi, Satoh, Ayumi, Ogi, Kazuhiro, Kikuchi, Takefumi, Suzuki, Hiromu, Mita, Hiroaki, Tanaka, Nobuyuki, Itoh, Fumio, Issa, Jean-Pierre J., Jair, Kam-Wing, Schuebel, Kornel E., Imai, Kohzoh, and Tokino, Takashi

Published
2003

21. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Author

Kantarjian, Hagop M, Roboz, Gail J, Kropf, Patricia L, Yee, Karen W L, O'Connell, Casey L, Tibes, Raoul, Walsh, Katherine J, Podoltsev, Nikolai A, Griffiths, Elizabeth A, Jabbour, Elias, Garcia-Manero, Guillermo, Rizzieri, David, Stock, Wendy, Savona, Michael R, Rosenblat, Todd L, Berdeja, Jesus G, Ravandi, Farhad, Rock, Edwin P, Hao, Yong, Azab, Mohammad, and Issa, Jean-Pierre J

Published
2017
Full Text
View/download PDF

28. Figure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Author

Jang, H. Josh, primary, Hostetter, Galen, primary, Macfarlane, Alexander W., primary, Madaj, Zachary, primary, Ross, Eric A., primary, Hinoue, Toshinori, primary, Kulchycki, Justin R., primary, Burgos, Ryan S., primary, Tafseer, Mahvish, primary, Alpaugh, R. Katherine, primary, Schwebel, Candice L., primary, Kokate, Rutika, primary, Geynisman, Daniel M., primary, Zibelman, Matthew R., primary, Ghatalia, Pooja, primary, Nichols, Peter W., primary, Chung, Woonbok, primary, Madzo, Jozef, primary, Hahn, Noah M., primary, Quinn, David I., primary, Issa, Jean-Pierre J., primary, Topper, Michael J., primary, Baylin, Stephen B., primary, Shen, Hui, primary, Campbell, Kerry S., primary, Jones, Peter A., primary, and Plimack, Elizabeth R., primary

Published
2023
Full Text
View/download PDF

29. Data from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Author

Jang, H. Josh, primary, Hostetter, Galen, primary, Macfarlane, Alexander W., primary, Madaj, Zachary, primary, Ross, Eric A., primary, Hinoue, Toshinori, primary, Kulchycki, Justin R., primary, Burgos, Ryan S., primary, Tafseer, Mahvish, primary, Alpaugh, R. Katherine, primary, Schwebel, Candice L., primary, Kokate, Rutika, primary, Geynisman, Daniel M., primary, Zibelman, Matthew R., primary, Ghatalia, Pooja, primary, Nichols, Peter W., primary, Chung, Woonbok, primary, Madzo, Jozef, primary, Hahn, Noah M., primary, Quinn, David I., primary, Issa, Jean-Pierre J., primary, Topper, Michael J., primary, Baylin, Stephen B., primary, Shen, Hui, primary, Campbell, Kerry S., primary, Jones, Peter A., primary, and Plimack, Elizabeth R., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Author

Jang, H. Josh, primary, Hostetter, Galen, primary, Macfarlane, Alexander W., primary, Madaj, Zachary, primary, Ross, Eric A., primary, Hinoue, Toshinori, primary, Kulchycki, Justin R., primary, Burgos, Ryan S., primary, Tafseer, Mahvish, primary, Alpaugh, R. Katherine, primary, Schwebel, Candice L., primary, Kokate, Rutika, primary, Geynisman, Daniel M., primary, Zibelman, Matthew R., primary, Ghatalia, Pooja, primary, Nichols, Peter W., primary, Chung, Woonbok, primary, Madzo, Jozef, primary, Hahn, Noah M., primary, Quinn, David I., primary, Issa, Jean-Pierre J., primary, Topper, Michael J., primary, Baylin, Stephen B., primary, Shen, Hui, primary, Campbell, Kerry S., primary, Jones, Peter A., primary, and Plimack, Elizabeth R., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer

Author

Ghosh, Jayashri, primary, Schultz, Bryant M., primary, Chan, Joe, primary, Wultsch, Claudia, primary, Singh, Rajveer, primary, Shureiqi, Imad, primary, Chow, Stephanie, primary, Doymaz, Ahmet, primary, Varriano, Sophia, primary, Driscoll, Melissa, primary, Muse, Jennifer, primary, Kleiman, Frida E., primary, Krampis, Konstantinos, primary, Issa, Jean-Pierre J., primary, and Sapienza, Carmen, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer

Author

Ghosh, Jayashri, primary, Schultz, Bryant M., primary, Chan, Joe, primary, Wultsch, Claudia, primary, Singh, Rajveer, primary, Shureiqi, Imad, primary, Chow, Stephanie, primary, Doymaz, Ahmet, primary, Varriano, Sophia, primary, Driscoll, Melissa, primary, Muse, Jennifer, primary, Kleiman, Frida E., primary, Krampis, Konstantinos, primary, Issa, Jean-Pierre J., primary, and Sapienza, Carmen, primary

Published
2023
Full Text
View/download PDF

37. Data from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer

Author

Ghosh, Jayashri, primary, Schultz, Bryant M., primary, Chan, Joe, primary, Wultsch, Claudia, primary, Singh, Rajveer, primary, Shureiqi, Imad, primary, Chow, Stephanie, primary, Doymaz, Ahmet, primary, Varriano, Sophia, primary, Driscoll, Melissa, primary, Muse, Jennifer, primary, Kleiman, Frida E., primary, Krampis, Konstantinos, primary, Issa, Jean-Pierre J., primary, and Sapienza, Carmen, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer

Author

Ghosh, Jayashri, primary, Schultz, Bryant M., primary, Chan, Joe, primary, Wultsch, Claudia, primary, Singh, Rajveer, primary, Shureiqi, Imad, primary, Chow, Stephanie, primary, Doymaz, Ahmet, primary, Varriano, Sophia, primary, Driscoll, Melissa, primary, Muse, Jennifer, primary, Kleiman, Frida E., primary, Krampis, Konstantinos, primary, Issa, Jean-Pierre J., primary, and Sapienza, Carmen, primary

Published
2023
Full Text
View/download PDF

43. Data from Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers

Author

Pickering, Curtis R., primary, Zhang, Jiexin, primary, Yoo, Suk Young, primary, Bengtsson, Linnea, primary, Moorthy, Shhyam, primary, Neskey, David M., primary, Zhao, Mei, primary, Ortega Alves, Marcus V., primary, Chang, Kyle, primary, Drummond, Jennifer, primary, Cortez, Elsa, primary, Xie, Tong-xin, primary, Zhang, Di, primary, Chung, Woonbok, primary, Issa, Jean-Pierre J., primary, Zweidler-McKay, Patrick A., primary, Wu, Xifeng, primary, El-Naggar, Adel K., primary, Weinstein, John N., primary, Wang, Jing, primary, Muzny, Donna M., primary, Gibbs, Richard A., primary, Wheeler, David A., primary, Myers, Jeffrey N., primary, and Frederick, Mitchell J., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Text from Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers

Author

Pickering, Curtis R., primary, Zhang, Jiexin, primary, Yoo, Suk Young, primary, Bengtsson, Linnea, primary, Moorthy, Shhyam, primary, Neskey, David M., primary, Zhao, Mei, primary, Ortega Alves, Marcus V., primary, Chang, Kyle, primary, Drummond, Jennifer, primary, Cortez, Elsa, primary, Xie, Tong-xin, primary, Zhang, Di, primary, Chung, Woonbok, primary, Issa, Jean-Pierre J., primary, Zweidler-McKay, Patrick A., primary, Wu, Xifeng, primary, El-Naggar, Adel K., primary, Weinstein, John N., primary, Wang, Jing, primary, Muzny, Donna M., primary, Gibbs, Richard A., primary, Wheeler, David A., primary, Myers, Jeffrey N., primary, and Frederick, Mitchell J., primary

Published
2023
Full Text
View/download PDF

48. Perspectives on This Article from Association between Folate Levels and CpG Island Hypermethylation in Normal Colorectal Mucosa

Author

Wallace, Kristin, primary, Grau, Maria V., primary, Levine, A. Joan, primary, Shen, Lanlan, primary, Hamdan, Randala, primary, Chen, Xinli, primary, Gui, Jiang, primary, Haile, Robert W., primary, Barry, Elizabeth L., primary, Ahnen, Dennis, primary, McKeown-Eyssen, Gail, primary, Baron, John A., primary, and Issa, Jean Pierre J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results